CIK 0001783328
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
TScan Therapeutics, Inc.
Sign in to watch- Ticker
- TCRX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 825282075
- Phone
- +1 857-399-9500
- Business address
- 830 WINTER STREET, WALTHAM, MA, 02451
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market buy Chief Executive Officer bought 25,000 shares at an average $3.59 ($89,821)
- 4 Open-market buy Director bought 1,359,792 shares at an average $1.88 ($2,559,154)
- 4 Open-market buy Chief Financial Officer bought 15,000 shares at $3.40 ($50,982)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Option exercise Chief Executive Officer acquired 48,670 shares (option exercise)
- 4 Open-market buy Chief Legal Officer bought 4,716 shares at $7.48 ($35,255)
- 4 Open-market buy Chief Financial Officer bought 5,000 shares at $6.32 ($31,585)
- 4 Open-market buy Chief Scientific Officer bought 5,000 shares at an average $6.22 ($31,097)
- 4 Open-market buy Chief Financial Officer bought 5,885 shares at $8.48 ($49,925)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
Page 5 of 6 · 119 filings